BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed MDGL catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:6cbd8d480fe792c38dce@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:MDGL P3 readout (est.): A Phase 3 Study to Evaluate the Effect of R
 esmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirr
 hosis (MAESTRO-NASH-OUTCOMES)
DESCRIPTION:A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinica
 l Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-
 OUTCOMES)\nNCT05500222 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Madriga
 l Pharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nDate precision: month (shown on the first da
 y)\nTicker MDGL (confidence 0.95)\nSource: https://clinicaltrials.gov/stud
 y/NCT05500222\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05500222
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
